Search

Deciphera Pharmaceuticals LLC has been granted a patent for a compound called 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea, which has potential therapeutic value in treating gastrointestinal stromal tumors (GIST) and other disorders. The patent describes pharmaceutical compositions containing the compound and other substances, intended for oral delivery. It also includes claims for methods of treating GIST by administering the compound to patients in need. The patent was filed by Corey Bloom and assigned to Deciphera Pharmaceuticals LLC. [Extracted from the article]

A patent application has been submitted for new therapeutic methods to treat acute myeloid leukemia (AML). The method involves using genetically modified T cells to target and kill cancer cells more effectively. By targeting specific molecules expressed in AML cells, the therapy can selectively target cancer cells while preserving healthy cells. The research aims to improve the prognosis for AML patients and address relapse and drug resistance. The patent application describes methods involving editing the genome of stem cells and administering antibodies or immune cells to improve the effectiveness of AML treatment. [Extracted from the article]

Deciphera Pharmaceuticals LLC has been issued a patent for compositions of a compound called 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea. The compound is a potential treatment for gastrointestinal stromal tumors (GIST) and other disorders. The patent describes the structure of the compound and its use in pharmaceutical compositions. The inventors claim that the compound, when administered orally, can effectively treat GIST in patients. The patent provides specific methods and formulations for delivering the compound to patients. [Extracted from the article]

This patent application discusses the development of amorphous kinase inhibitor formulations and their potential use in treating certain genetic developmental abnormalities and cancers. The focus is on the c-KIT protein, which plays a role in cellular signaling and various cellular processes. The application describes pharmaceutical compositions that contain amorphous forms of the compound, which may have improved pharmacokinetic profiles and fast release. Additionally, the application mentions the need for oral formulations of PDGFRa inhibitors for the treatment of solid and hematological cancers. Specifically, the patent application includes a method of treating gastrointestinal stromal tumors using a tablet formulation containing the compound in amorphous form. [Extracted from the article]

A patent has been issued for a combination therapy for the treatment of gastrointestinal stromal tumor (GIST). The therapy involves the use of a c-KIT inhibitor in combination with an inhibitor of the MAPKAP kinase signaling pathway. The combination has been shown to lead to cell death, apoptosis, and prolonged cell stasis of GIST cells, as well as enhanced tumor regression in vivo. The therapy is particularly effective for GIST patients who are resistant to imatinib treatment. [Extracted from the article]

A patent application is currently being reviewed for a compound called 1-(4-Bromo-5-(1-Ethyl-7-(Methylamino)-2-Oxo-1,2-Dihydro-1,6-Naphthyridin-3-Yl)-2-Fluoropheyl)-3-Phenylurea, which is being developed as a potential treatment for various disorders, including cancer. The application describes the structure of the compound and its potential use in pharmaceutical compositions. The inventors emphasize the need for oral formulations of inhibitors for certain genes associated with cancer. The composition described in the application is specifically for treating gastrointestinal stromal tumors and includes a solid dispersion of the compound along with other ingredients. The application provides detailed information about the composition and its use in treating these tumors. [Extracted from the article]

Deciphera Pharmaceuticals LLC has been issued a patent for a compound called (methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea. The compound is a potential treatment for gastrointestinal stromal tumors (GIST) and other disorders. The patent describes the structure of the compound and its use in pharmaceutical compositions. The inventors claim that the compound, when administered orally, can effectively treat GIST in patients. The patent provides specific methods and formulations for delivering the compound to patients. [Extracted from the article]

The USPTO has published a patent application for a pharmaceutical composition used in the treatment of gastrointestinal stromal tumors (GIST) and other disorders. The composition includes a compound represented by Formula (I) and various substances such as hydroxypropyl methyl cellulose acetate succinate, microcrystalline cellulose, lactose monohydrate, crospovidone, silicon dioxide, and magnesium stearate. The patent application also discusses the importance of tyrosine phosphorylation in cellular signaling and its role in various cellular processes. For more information, readers are advised to consult the full patent application. [Extracted from the article]

10x Genomics, a leader in single cell and spatial biology, has announced the availability of its Xenium multi-modal cell segmentation kit and the launch of a new Xenium gene panel for immuno-oncology applications. These products expand the Xenium single cell spatial analysis menu and were developed based on customer feedback. 10x Genomics plans to release more products for Xenium in the future to meet the specific research needs of their customers. [Extracted from the article]

A patent has been issued for compositions of a compound called 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea. The patent was filed by inventors from Deciphera Pharmaceuticals LLC and published online on March 5, 2024. The compound is a c-KIT inhibitor and has potential therapeutic value in the treatment of gastrointestinal stromal tumors (GIST) and other disorders. The patent describes pharmaceutical compositions containing the compound and one or more pharmaceutically acceptable carriers, excipients, or diluents. The compositions aim to provide stable oral formulations with good therapeutic properties. [Extracted from the article]

A patent has been issued for compositions of a compound called 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea. The patent is assigned to Deciphera Pharmaceuticals LLC and was filed by inventors Corey Bloom, Scott Bone, Fred Jordan, and Michael D. Kaufman. The compound is a c-KIT inhibitor and has potential therapeutic value in the treatment of gastrointestinal stromal tumors (GIST) and other disorders. The patent describes pharmaceutical compositions containing the compound and one or more pharmaceutically acceptable carriers, excipients, or diluents. The compositions aim to provide stable oral formulations with good therapeutic properties. [Extracted from the article]

A patent has been issued for compositions of a compound called 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea. This compound is a broad-spectrum c-KIT inhibitor and has potential therapeutic value in the treatment of refractory gastrointestinal stromal tumors (GIST) and other disorders. The patent describes pharmaceutical compositions containing the compound and one or more pharmaceutically acceptable carriers, excipients, or diluents. The compositions are intended for oral delivery and have good therapeutic properties. The patent was filed by Deciphera Pharmaceuticals LLC and published in February 2024. [Extracted from the article]

A patent has been issued for compositions of a compound called 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea. This compound is a broad-spectrum c-KIT inhibitor and has potential therapeutic value in the treatment of refractory gastrointestinal stromal tumors (GIST) and other disorders. The patent describes pharmaceutical compositions containing the compound and one or more pharmaceutically acceptable carriers, excipients, or diluents. The compositions aim to provide stable oral formulations with good therapeutic properties. The patent was filed by Deciphera Pharmaceuticals LLC and published in December 2023. [Extracted from the article]

Deciphera Pharmaceuticals LLC has been issued a patent for compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea. The patent describes the compound's structure and its potential use in pharmaceutical preparations. The compound is a c-KIT inhibitor and may have therapeutic value in the treatment of refractory gastrointestinal stromal tumors (GIST) and other disorders. The patent also mentions the link between mutations in the PDGFRa gene and various solid and hematological cancers, and the need for oral formulations of PDGFRa inhibitors. [Extracted from the article]

A patent has been issued for compositions of a compound called 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea. The patent was filed by inventors from Deciphera Pharmaceuticals LLC and published online on December 19, 2023. The compound is a broad-spectrum c-KIT inhibitor and has potential therapeutic value in the treatment of refractory gastrointestinal stromal tumors (GIST) and other disorders. The patent describes pharmaceutical compositions containing the compound and one or more pharmaceutically acceptable carriers, excipients, or diluents. The compositions aim to provide stable oral formulations with good therapeutic properties. [Extracted from the article]

This document is a patent application for a pharmaceutical composition that aims to provide stable and effective treatments for refractory gastrointestinal stromal tumors (GIST) and other disorders. The composition includes a compound represented by Formula (I) and hydroxypropyl methyl cellulose acetate succinate, along with other ingredients such as microcrystalline cellulose, lactose monohydrate, crospovidone, silicon dioxide, and magnesium stearate. The patent application specifies that the composition may contain anilinic substances in certain percentages by weight. Inventors Corey Bloom, Scott Bone, Fred Jordan, and Michael D. Kaufman propose these compositions to address the importance of the c-KIT protein and the PDGFRa gene in various cancers and genetic disorders. For more detailed information, readers can refer to the full patent application. [Extracted from the article]

The USPTO has published a patent application titled "Compositions Of 1-(4-Bromo-5-(1-Ethyl-7-(Methylamino)-2-Oxo-1,2-Dihydro-1,6-Naphthyridin-3-Yl)-2-Fluoropheyl)-3-Phenylurea" online. The inventors discuss the role of c-KIT and PDGFRa kinases in cellular signaling and their connection to different cancers. They propose compositions and pharmaceutical formulations containing a compound of Formula (I) for the treatment of refractory gastrointestinal stromal tumors (GIST) and other disorders. The compositions aim to provide stable and effective oral formulations of inhibitors for these kinases. The patent application provides detailed information on the composition and its various embodiments. [Extracted from the article]

A targeted oral therapy called bezuclastinib has shown promise in reducing disease burden and improving symptoms for patients with nonadvanced systemic mastocytosis, a rare blood disorder. In a Phase II trial, all participants treated with bezuclastinib achieved at least a 50% reduction in markers of disease burden, and 63% reported eased disease symptoms within 12 weeks. The therapy, which specifically targets the KIT D816V gene mutation associated with the disorder, demonstrated minimal side effects and no serious adverse events. Further research is underway to determine the optimal dosage and compare bezuclastinib against a placebo. [Extracted from the article]

A patent has been issued for compositions of a compound called 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea. The compound is a potential inhibitor for c-KIT and PDGFRa kinases, which are involved in various cancers and genetic disorders. The patent describes pharmaceutical compositions containing the compound and one or more anilinic substances, which could be used for oral delivery. The inventors claim that these compositions have therapeutic value for the treatment of refractory gastrointestinal stromal tumors (GIST) and other disorders. The patent was filed by Deciphera Pharmaceuticals LLC and published in October 2023. [Extracted from the article]

Keywords: Genetics; Stem Cell Research EN Genetics Stem Cell Research 73 73 1 10/24/23 20231027 NES 231027 2023 OCT 23 (NewsRx) -- By a News Reporter-Staff News Editor at Stem Cell Week -- New research on genetics is the subject of a new report. Keywords for this news article include: University of California San Diego (UCSD), La Jolla, California, United States, North and Central America, Genetics, Stem Cell Research. [Extracted from the article]

"Prior immunohistochemistry characterization of BCOR-mutated uterine sarcomas suggests that activation of the CDK4 kinase complex occurs in this rare subset of uterine sarcomas, which may be therapeutically relevant as specific CDK4 inhibitor drugs are clinically available and currently FDA-approved in estrogen receptor-positive breast cancer (de Duenas E. M. et al. (2018) Clin. In some embodiments of any of the above embodiments, the targeted therapeutic is selected from the group consisting of a CDK inhibitor, an MDM2 inhibitor, a tyrosine kinase inhibitor, a MEK inhibitor, an mTOR inhibitor, and a Hh inhibitor. BCOR-rearranged uterine sarcomas were found to exhibit frequent genomic alterations leading to CDK4 activation, suggesting that most BCOR-mutated uterine sarcoma patients may be eligible for clinical trials with CDK4 or MDM2 inhibitors and the like, including without limitation palbociclib. In contrast, activity of the CDK4 kinase is inhibited by p16 (also known as p16 SP INK4a sp and/or cyclin-dependent kinase inhibitor 2A, encoded by the CDKN2A gene), which binds to the cyclin D1-CDK4 complex and inhibits CDK4 kinase activity (Serrano, M. (1997) Exp. [Extracted from the article]

According to the news editors, the research concluded: "Moreover, using small EVs isolated from ovarian cancer ascites, it was shown that recurrent disease is characterized by a much higher abundance of CD117 on EVs than primary tumor." Keywords: Business; Cancer; Genetics; Gynecology; Health and Medicine; Oncology; Ovarian Cancer; Women's Health EN Business Cancer Genetics Gynecology Health and Medicine Oncology Ovarian Cancer Women's Health 2023 MAR 7 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Research findings on ovarian cancer are discussed in a new report. [Extracted from the article]

Also provided herein are compositions that include any of the single-chain chimeric polypeptides described herein, nucleic acids that encode any of the single-chain chimeric polypeptides described herein, and cells that include any of the nucleic acids that encode any of the single-chain chimeric polypeptides described herein. Keywords: Amino Acids; Bioengineering; Biologics; Biotechnology; Blood Coagulation Factors; Business; Enzymes and Coenzymes; Genetic Engineering; Genetically-Engineered Proteins; Genetics; HCW Biologics Inc.; Health and Medicine; Hematology; Neutral Amino Acids; Peptide Hydrolases; Protease; Serine; Serine Endopeptidases; Stem Cell Research; Thrombin EN Amino Acids Bioengineering Biologics Biotechnology Blood Coagulation Factors Business Enzymes and Coenzymes Genetic Engineering Genetically-Engineered Proteins Genetics HCW Biologics Inc. Health and Medicine Hematology Neutral Amino Acids Peptide Hydrolases Protease Serine Serine Endopeptidases Stem Cell Research Thrombin 549 549 1 03/24/23 20230302 NES 230302 2023 MAR 2 (NewsRx) -- By a News Reporter-Staff News Editor at Stem Cell Week -- A patent application by the inventor Wong, Hing (Miramar, FL, US), filed on July 21, 2022, was made available online on February 9, 2023, according to news reporting originating from Washington, D.C., by NewsRx correspondents. Tissue factor, normally not in contact with circulating blood, initiates the coagulation cascade upon exposure to the circulating coagulation serine protease factors. [Extracted from the article]